Table 5.
Comparison of baseline clinical characteristics between Taiwan registry and representative PAD registries
| TwPAD n = 1005 |
PORTRAIT n = 1275 |
K-VIS ELLA n = 3073 |
XLPAD n = 2162 |
|
|---|---|---|---|---|
| Age, y | 70.5 ± 11.5 | 67.6 ± 9.4 | 68.4 ± 9.5 | 66.2 ± 10.2 |
| Male, n (%) | 596 (59.3) | 793 (62.2) | 2523 (82.1) | 1630 (75.4) |
| BMI | 24.7 ± 4.5 | 29.0 ± 6.4 | 23.5 ± 3.6 | - |
| Former or current smoker, n (%) | 408 (40.6) | 1134 (89.2) | 1790 (58.2) | - |
| Hypertension, n (%) | 767 (76.3) | 1017 (79.8) | 2257 (73.4) | 1102 (51.0) |
| Diabetes, n (%) | 685 (68.2) | 398 (31.2) | 1378 (58.0) | 112 (23.4) |
| Hyperlipidemia, n (%) | 730 (72.6) | 1015 (79.6) | 1195 (38.9) | 1761 (81.5) |
| Heart failure, n (%) | 180 (17.9) | 127 (10.0) | - | 12 (2.5) |
| Atrial fibrillation, n (%) | 113 (11.2) | 143 (11.2) | - | 35 (7.3) |
| Prior PCI, n (%) | 319 (31.7) | 282 (22.1) | - | 56 (11.7) |
| Prior CABG, n (%) | 33 (32.8) | 243 (19.1) | - | 45 (9.4) |
| Prior LEAD intervention, n (%) | 601 (59.8) | 253 (19.8) | 299 (9.7) | 57 (11.9) |
| Aspirin, n (%) | 478 (47.6) | - | 2592 (84.3) | 1180 (54.6) |
| Clopidogrel, n (%) | 463 (46.1) | - | 2522 (82.1) | 623 (28.9) |
| Cilostazol, n (%) | 565 (56.2) | 141 (11.8) | - | - |
| ACEi/ARB, n (%) | 397 (39.5) | 724 (60.1) | 1366 (44.5) | 862 (39.9) |
| Beta blocker, n (%) | 390 (38.8) | - | 1051 (34.2) | 857 (39.6) |
| Statin, n (%) | 270 (26.9) | 966 (80.6) | 2127 (69.2) | 1090 (50.4) |
| Antidiabetic Agents, n (%) | 548 (54.5) | - | 578 (18.8) | - |
ACEi = angiotensin-converting enzyme inhibitors; ARB = angiotensin II receptor blockers; GLP-1 receptor agonist = glucagon-like peptide-1 receptor agonists; LEAD = lower extremity arterial disease; SGLT2-I = sodium-glucose transport protein 2 inhibitor.